Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL741805 | 0.92 | HTR6 (0.38) | HTR6HTR2CCD274PNMT | |
| SCHEMBL739933 | 0.86 | PNMT (0.39) | HTR6HTR2CPNMTCYP3A4 | |
| SCHEMBL742092 | 0.82 | HTR6 (0.44) | HTR6HTR2CCD274CYP3A4 | |
| SCHEMBL742328 | 0.82 | KMT2A (0.46) | HTR6HTR2C | |
| SCHEMBL743880 | 0.82 | HTR6 (0.54) | HTR6HTR2CPNMTCYP3A4 | |
| SCHEMBL743386 | 0.81 | HTR6 (0.56) | HTR6HTR2CCYP3A4 | |
| SCHEMBL742252 | 0.80 | HTR6 (0.42) | HTR6HTR2CPNMTCYP3A4 | |
| SCHEMBL763083 | 0.79 | HTR6 (0.53) | HTR6HTR2CCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL741198 | 0.79 | HTR6 (0.36) | HTR6HTR2CPNMTCYP3A4 | |
| SCHEMBL743820 | 0.78 | HTR6 (0.43) | HTR6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | claimed |
| EP-2134714-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | Biovitrum AB (publ) (SE) | 2009-12-23 | — | — | EP | claimed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | claimed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | claimed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| EP-2134714-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | Biovitrum AB (publ) (SE) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | HTR6 1/4885HTR2C 8/4885CD274 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.